FDA accepts Adcetris sBLA for expanded HL, ALCL use
This article was originally published in Scrip
Executive Summary
Shares of Seattle Genetics rose 3.5% on 14 May on word the US FDA had accepted for filing the firm's supplement to the biologics license application (sBLA) seeking to expand the labeling for Adcetris (brentuximab vedotin) as a retreatment and extended use beyond 16 cycles of therapy in relapsed Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (sALCL).